Sponsored
Meeta Gulyani, Ecolab Life Sciences, shares where biomanufacturing is headed next and why the relationship between drug developers and their suppliers is changing along with it.
|Articles|July 1, 2002
FDA ISSUES STATEMENT ON ACRYLAMIDE IN FOODS
Current information is "not sufficient" for FDA to determine the public health impact of acrylamide in foods, FDA Deputy Commissioner Lester M. Crawford, D.V.M., said in a statement.
Advertisement
FDA ISSUES STATEMENT ON ACRYLAMIDE IN FOODS -- Current information is "not sufficient" for FDA to determine the public health impact of acrylamide in foods, FDA Deputy Commissioner Lester M. Crawford, D.V.M., said in a statement. "FDA is unaware of any present data regarding acrylamide that would cause FDA to alter its current dietary recommendations for consumers." http://www.fda.gov/bbs/topics/NEWS/2002/NEW00817.html
Advertisement
Related to this article
Novo Nordisk licenses a once-weekly oral GLP-1/GIP candidate, uniQure reports 48-month Huntington’s disease data, and AstraZeneca invests $2 billion in Summit Therapeutics.
Novo gains global rights, excluding Greater China, to HRS-1596, a phase 1-ready GLP-1/GIP dual receptor agonist that Hengrui says has potential for once-weekly oral dosing in obesity and type 2 diabetes.
NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.
Ivonescimab, in phase 3 trials across 8 tumor types, will be paired with sonesitatug vedotin in new gastrointestinal cancer trials.
Today’s biopharma news highlights how new data could reduce treatment burden, improve excipient information sharing, and shape future options for patients with difficult-to-treat cancers.
Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.
Advertisement
Advertisement